The Precision Medicine Access and Value Program aims to bring together a broad spectrum of experts from UCSF and beyond to examine and propose actions to address critical issues that impact the effective translation of precision medicine innovations into practice and policy. Precision medicine interventions such as genomic tests and targeted therapies have the potential to transform health care but persistent barriers to clinical integration remain, including uncertainty regarding the economic value of novel approaches and a related lack of insurer coverage. Patients, healthcare practitioners, researchers, industry, payers, and policymakers need evidence about these interventions to guide the effective and equitable application of precision medicine to improve health for individuals and populations. This Program reflects a commitment to improve health and health care within local, state, national, and international communities, with a special focus on improving the health of underserved populations.
The Precision Medicine Access and Value Program is part of UCSF Precision Medicine and is led by the Center for Translational and Policy Research on Precision Medicine (TRANSPERS), located in the UCSF Department of Clinical Pharmacy. TRANSPERS has been a leading research organization for developing evidence-based information about the real-world use of precision medicine technologies since its founding in 2008. Its mission is to provide objective evidence on insurer coverage, economic value, and stakeholder decision-making to support the implementation of precision medicine into clinical care and health policy.
TRANSPERS and UCSF Precision Medicine are seeking feedback on the following items to inform the direction and activities of the program, to help ensure value to participating stakeholders and positively impact patients and the precision medicine ecosystem:
- Facilitation of studies and multi-disciplinary working groups to address evidence gaps on access to care, utilization of services, insurer coverage and reimbursement, economic value, and policy decision-making
- Methodologies that include systematic reviews, cost-effectiveness analysis, real-world evidence studies, qualitative and mixed methods research, and stakeholder engagement
- Collaborative research opportunities in health services research and health policy; access, utilization, and implementation; payer coverage policies; economic value; and health equity impact
- Opportunities to contribute and draw on expertise in evidence synthesis; health economic modeling; real-world evidence studies; clinical and policy decision-making, particularly payer coverage and reimbursement; mixed methods analyses; and stakeholder engagement & consensus development
Additional activities to support stakeholder work to assess the value of precision medicine innovations and translate them into equitable practices and policies
For more information, see announcement.
Please send feedback to [email protected].
